Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.
The independent analysis covers the first half-year of 2019 and was published on Monday, December 04, 2018, where First Berlin Equity Research reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the company’s website.
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168